EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSVVUG00000007873
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSVVUG00000015205
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSVVUG00000018025
Gene Symbol: CHRNA7
3 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSVVUG00000001790
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSVVUG00000007880
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSVVUG00000029216
Gene Symbol: CMA1
4 Cross references
293 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSVVUG00000025128
Gene Symbol: F2R
1 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSVVUG00000026767
Gene Symbol: F2
3 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSVVUG00000021851
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSVVUG00000019755
Gene Symbol: F7
3 Cross references
274 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSVVUG00000019750
Gene Symbol: F10
3 Cross references
237 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSVVUG00000012227
Gene Symbol: F11
3 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).